The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the clinical response is inadequate. CAN-2409 is a viral immunotherapy approach that induces tumor-infiltrating T-cells and a consequent PD-L1 up-regulation. A combination of CAN-2409 added to standard of care (SOC) checkpoint inhibitors may lead to improved long-term outcomes for patients with NSCLC who have suboptimal response to ICI therapy.

开始日期2020-10-13

申办/合作机构

Candel Therapeutics, Inc.

[+1]

NCT03603405

/ Recruiting临床1/2期IIT

Phase I-II Study Evaluating HSV-tK + VALACYCLOVIR GENE THERAPY Combination with Radiotherapy and Chemotherapy for Newly Diagnosed Anaplastic Astrocytoma and Glioblastoma Multiforme.

Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).

开始日期2018-02-28

申办/合作机构

The Methodist Hospital Research Institute

NCT03576612

/ Completed临床1期

Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined with Standard of Care for Newly Diagnosed High-Grade Gliomas

The purpose of this phase I trial is to test the safety of combining GMCI, an immunostimulator, plus nivolumab, an immune checkpoint inhibitor (ICI), with standard of care radiation therapy, and temozolomide in treating patients with newly diagnosed high-grade gliomas.
Gene Mediated Cytotoxic Immunotherapy (GMCI) involves the use of aglatimagene besadenovec (AdV-tk) injection into the tumor site and oral valacyclovir to kill tumor cells and stimulate the immune system. Nivolumab is an immune checkpoint inhibitor that may also stimulate the immune system by blocking the PD-1 immune suppressive pathway. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors and temozolomide is a chemotherapy drug that kills tumor cells. Giving GMCI, nivolumab, radiation therapy, and temozolomide may work better in treating patients with high-grade gliomas

开始日期2018-02-27

申办/合作机构

Candel Therapeutics, Inc.

[+2]

100 项与 Aglatimagene besadenovec 相关的临床结果

登录后查看更多信息

100 项与 Aglatimagene besadenovec 相关的转化医学

登录后查看更多信息

100 项与 Aglatimagene besadenovec 相关的专利（医药）

登录后查看更多信息

项与 Aglatimagene besadenovec 相关的文献（医药）

2025-02-01·Biochemical genetics

The Combinatorial Effect of Ad-IL-24 and Ad-HSV-tk/GCV on Tumor Size, Autophagy, and UPR Mechanisms in Multiple Myeloma Mouse Model

Article

作者: Hosseini, Seyed Younes ; Irani, Shiva ; Abdoli, Asghar ; Baesi, Kazem ; Poorghobadi, Shima ; Sadat, Seyed Mehdi

Multiple myeloma is a type of malignant neoplasia whose treatment has changed over the past decade. This study aimed to investigate the effects of combination of Adenovector-carrying interleukin-24 and herpes simplex virus 1 thymidine kinase/ganciclovir on tumor growth, autophagy, and unfolded protein response mechanisms in mouse model of multiple myeloma. Six groups of mice, including Ad-HSV-tk/GCV, Ad-IL-24, Ad-HSV-tk/IL-24, Ad-GFP, and positive and negative controls, were investigated, and each group was injected every 72 h. The tumor size was measured several times. The expression of LC3B evaluated through western blotting and ASK-1, CHOP, Caspase-3, and ATF-6 genes in the UPR and apoptosis pathways were also analyzed by the quantitative polymerase chain reaction (qPCR) method. The present results showed that the injection of Ad-HSV-tk/GCV, Ad-HSV-tk/IL-24, and metformin reduced the tumor size. The expression of LC3B was significantly higher in the treatment groups and positive control groups compared to the negative control group. The expression of CHOP, caspase-3, and ATF-6 genes was significantly higher in the Ad-IL-24 group compared to the other treatment groups. Besides, the ASK-1 expression was significantly lower in the Ad-IL-24 group as compared to the other groups. Overall, the results indicated that the presence of the HSV-tk gene in the adenovectors reduced the size of tumors and induced autophagy by triggering the expression of LC3B protein. The presence of the IL-24 might affect tumor growth but not as much the therapeutic effect of HSV-tk. Furthermore, the results indicated that co-administration of IL-24 and HSV-tk had no synergistic effect on tumor size control.

2025-02-01·Cancer research communications

Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy

Article

作者: Richardson, Erin ; Li, Zhi ; Withers, David R. ; Tak, Paul P. ; Willis, Claire ; Idris, Suaad ; Barone, Francesca ; Diers, Anne R. ; Guo, Qiuchen

Abstract:

CAN-2409 is a replication-defective adenovirus that delivers the herpes simplex virus–thymidine kinase gene to infected cells. Intratumoral administration of CAN-2409, followed by prodrug, results in the formation of a toxic metabolite able to induce immunogenic cell death, exposure of tumor-associated antigens, and activation of local and systemic immune responses. We used a dynamic labeling model with MC38 tumor cells implanted in photoconvertible Kaede mice. Violet light was used to label the tumor microenvironment (TME), distinguishing retained versus newly entering cells and allowing real-time monitoring of immune compartment changes within tumors. Administration of CAN-2409 + prodrug led to control of tumor growth and significantly increased effector CD8+ T-cell responses. Photolabeling of the TME revealed that rather than enhancing recruitment of T cells to the tumor, CAN-2409 altered the TME whereby newly entering and retained CD8+ T cells were significantly more proliferative. CAN-2409 supported reinvigoration of tumor-associated antigen–specific CD8+ T cells and expansion of regulatory T cells of an altered phenotype. Moreover, the combination of CAN-2409 + prodrug and anti–CTLA-4 antibody treatment further improved control of tumor growth, in part by the enhanced CD8+ T-cell–mediated effector function and diminished regulatory T cell–mediated immunosuppression. Collectively, these data defined at least two temporally distinct pathways underpinning the mechanism of action of CAN-2409 that overcome cell exhaustion and decrease immune suppression. The results also support the rationale for future clinical trials of CAN-2409 treatment combined with anti–CTLA-4 antibody therapy.

Significance::

This study utilized a novel photoconvertible mouse tumor model to track immune cell trafficking upon treatment with an investigational viral immunotherapy (CAN-2409), revealing enhanced T-cell responses after viral immunotherapy associated with local proliferation of T cells within tumors that could further enhance antitumor efficacy in combination with immune checkpoint inhibitors. These findings define temporally and spatially distinct interactions of immune cells that could be harnessed by novel therapeutics.

2023-10-03·Expert opinion on biological therapy

Oncolytic virotherapies for pediatric tumors

Review

作者: Atchley, Travis J ; Johnston, James M ; Laskay, Nicholas Mb ; Gross, Evan G ; Estevez-Ordonez, Dagoberto ; Markert, James M ; Hamo, Mohammad A

INTRODUCTION:

Many pediatric patients with malignant tumors continue to suffer poor outcomes. The current standard of care includes maximum safe surgical resection followed by chemotherapy and radiation which may be associated with considerable long-term morbidity. The emergence of oncolytic virotherapy (OVT) may provide an alternative or adjuvant treatment for pediatric oncology patients.

AREAS COVERED:

We reviewed seven virus types that have been investigated in past or ongoing pediatric tumor clinical trials: adenovirus (AdV-tk, Celyvir, DNX-2401, VCN-01, Ad-TD-nsIL-12), herpes simplex virus (G207, HSV-1716), vaccinia (JX-594), reovirus (pelareorep), poliovirus (PVSRIPO), measles virus (MV-NIS), and Senecavirus A (SVV-001). For each virus, we discuss the mechanism of tumor-specific replication and cytotoxicity as well as key findings of preclinical and clinical studies.

EXPERT OPINION:

Substantial progress has been made in the past 10 years regarding the clinical use of OVT. From our review, OVT has favorable safety profiles compared to chemotherapy and radiation treatment. However, the antitumor effects of OVT remain variable depending on tumor type and viral agent used. Although the widespread adoption of OVT faces many challenges, we are optimistic that OVT will play an important role alongside standard chemotherapy and radiotherapy for the treatment of malignant pediatric solid tumors in the future.

125

项与 Aglatimagene besadenovec 相关的新闻（医药）

2025-05-13

·ir.candeltx.com

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Preparations on track for Biologics License Application (BLA) for CAN-2409 in intermediate-to-high-risk localized prostate cancer, with submission expected in Q4 2026 Recently announced both prolonged median overall survival (mOS) and a long tail of survival in an open label phase 2a clinical trial of CAN-2409 in advanced non-small cell lung cancer (NSCLC) patients, non-responsive to immune checkpoint inhibitor (ICI) treatment, particularly those patients with non-squamous histology Recently announced notable improvement in mOS after experimental treatment with CAN-2409 compared to the control group based on a randomized controlled phase 2a clinical trial of CAN-2409 in borderline resectable pancreatic adenocarcinoma (PDAC) Recent publication in Neuro-Oncology of encouraging clinical and immunological biomarker data based on a phase 1b clinical trial of the combination of CAN-2409 and nivolumab plus standard of care in newly diagnosed high-grade glioma On track to report biomarker and initial survival data from ongoing phase 1b clinical trial evaluating repeat doses of CAN-3110 in patients with recurrent high-grade glioma (rHGG), expected in Q4 2025 NEEDHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today financial results for the first quarter ended March 31, 2025, and provided a corporate update. “During the quarter, we continued our strong momentum of compelling clinical evidence, reinforcing our promising pipeline of pan solid tumor immunotherapies,” said Paul Peter Tak, MD PhD FMedSci, President and CEO of Candel. “Our primary focus for 2025 remains on working toward CAN-2409’s BLA submission for prostate cancer, which we believe represents a very significant unmet medical need and opportunity for value creation. In this indication, we observed the ability of CAN-2409 to reduce the risk of prostate cancer recurrence compared to standard of care, through meeting the primary endpoint agreed with the FDA under a Special Protocol Assessment in a phase 3 clinical trial. We are now focusing on executing strategic preparations for potential commercialization, to ensure that, if approved, CAN-2409 is immediately available to patients with localized prostate cancer.” Dr. Tak continued, “CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, continues to demonstrate meaningful overall survival benefits in patients with advanced NSCLC, non-responsive to immune checkpoint inhibitors, as well as in patients with borderline resectable PDAC. The totality of data showing notable extension of survival based on both phase 2a clinical trials in NSCLC and PDAC, respectively, suggests that CAN-2409 has the potential to represent a transformative treatment option for patients with difficult-to-treat solid tumors. The FDA Fast Track Designation for each indication further validates the potential of this novel approach to address significant unmet medical needs in oncology.” First Quarter 2025 & Recent Highlights CAN-2409 – Prostate Cancer Positive phase 3 results from the CAN-2409 clinical trial in intermediate-to-high risk localized prostate cancer have been selected for an oral presentation at the upcoming 2025 ASCO Annual Meeting, taking place May 30 to June 3, 2025, in Chicago, IL. This phase 3 study was conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA), meaning that certain data generated from this study could be sufficient for the Company to seek regulatory approval for CAN-2409 in this indication. The Company continues to work toward a Q4 2026 BLA submission for prostate cancer, following the positive topline data from its multicenter, randomized, placebo-controlled phase 3 clinical trial evaluating CAN-2409 in intermediate-to-high-risk localized prostate cancer patients. The FDA previously granted Fast Track Designation for CAN-2409 for the treatment of localized primary prostate cancer. Positive phase 3 results from the CAN-2409 clinical trial in intermediate-to-high risk localized prostate cancer have been selected for an oral presentation at the upcoming 2025 ASCO Annual Meeting, taking place May 30 to June 3, 2025, in Chicago, IL. This phase 3 study was conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA), meaning that certain data generated from this study could be sufficient for the Company to seek regulatory approval for CAN-2409 in this indication. The Company continues to work toward a Q4 2026 BLA submission for prostate cancer, following the positive topline data from its multicenter, randomized, placebo-controlled phase 3 clinical trial evaluating CAN-2409 in intermediate-to-high-risk localized prostate cancer patients. The FDA previously granted Fast Track Designation for CAN-2409 for the treatment of localized primary prostate cancer. CAN-2409 - Pancreatic Cancer Positive final survival data from the randomized controlled phase 2a clinical trial of CAN-2409 in borderline resectable PDAC demonstrated notable improvement in overall survival compared to standard of care. Patients who had received experimental treatment with CAN-2409 and chemoradiotherapy achieved a mOS of 31.4 months versus 12.5 months observed in the control arm treated with chemoradiotherapy. Notably, three long-term survivors in the CAN-2409 arm remained alive at 66.0, 63.6, and 35.8-months post-treatment, whereas only one patient from the control arm was still alive at the time of data cut-off (February 20, 2025). Patients in the CAN-2409 arm were stable at the time of last follow up with minimal maintenance therapy and, despite previous recurrence, experienced extended and ongoing post-progression survival, further highlighting the sustained benefit of CAN-2409, even in metastatic disease. The FDA previously granted Orphan Drug Designation and Fast Track Designation for CAN-2409 in borderline resectable PDAC. Positive final survival data from the randomized controlled phase 2a clinical trial of CAN-2409 in borderline resectable PDAC demonstrated notable improvement in overall survival compared to standard of care. Patients who had received experimental treatment with CAN-2409 and chemoradiotherapy achieved a mOS of 31.4 months versus 12.5 months observed in the control arm treated with chemoradiotherapy. Notably, three long-term survivors in the CAN-2409 arm remained alive at 66.0, 63.6, and 35.8-months post-treatment, whereas only one patient from the control arm was still alive at the time of data cut-off (February 20, 2025). Patients in the CAN-2409 arm were stable at the time of last follow up with minimal maintenance therapy and, despite previous recurrence, experienced extended and ongoing post-progression survival, further highlighting the sustained benefit of CAN-2409, even in metastatic disease. The FDA previously granted Orphan Drug Designation and Fast Track Designation for CAN-2409 in borderline resectable PDAC. CAN-2409 – Non-Small Cell Lung Cancer In March, the Company reported final survival data from its phase 2a clinical trial of CAN-2409 in patients with stage III/IV NSCLC, inadequately responding to ICI treatment. In patients with an inadequate response to ICI treatment (Cohort 1+2, n=46), mOS was 24.5 months. In patients with progressive disease, despite ICI treatment (Cohort 2, n=41), mOS was 21.5 months, which is markedly longer than the 9.8–11.8 months of survival reported in published literature1,2 in the same patient population receiving standard of care of docetaxel chemotherapy. 37% of patients with progressive disease at enrollment were still alive > 24 months after CAN-2409 treatment at the time of the March 3, 2025 data cut, suggesting a long tail of survival. 14/15 patients with overall survival > 24 months and 9/9 patients with overall survival > 30 months had non-squamous NSCLC. In patients with non-squamous NSCLC and progressive disease despite ICI (cohort 2, n=33), observed mOS was 25.4 months after CAN-2409 treatment. A decrease in the size of uninjected tumors was observed in 69% of patients with multiple lesions (n=35), indicating that a local injection is associated with a systemic anti-tumor immune response. CAN-2409 maintained its generally favorable safety and tolerability profile throughout the extended follow-up period. The FDA previously granted Fast Track Designation for CAN-2409 for the treatment of NSCLC. Recent Corporate Events In March 2025, the Company entered a strategic, commercial collaboration with IDEA Pharma, a Division of SAI MedPartners (IDEA). Under this agreement, IDEA will provide strategic commercial input throughout the development and commercialization process for Candel’s lead asset, CAN-2409. Through this collaboration, Candel will gain access to a dedicated team of experts with extensive experience in oncology commercialization and go-to-market strategy optimization. In March 2025, the Company appointed Elizabeth M. Jaffee, M.D., to its Research Advisory Board (RAB). Dr. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, brings her extensive expertise to the RAB, which is important in light of the Company’s focus on borderline resectable pancreatic cancer. Publication Manuscript published in the March 2025 online edition of Neuro-Oncology, reporting results of a phase 1b clinical trial exploring safety and tolerability of the combination of CAN-2409 plus prodrug (valacyclovir) and nivolumab, in addition to standard of care (neurosurgery, radiotherapy, and temozolomide), in patients with newly diagnosed rHGG. In March, the Company reported final survival data from its phase 2a clinical trial of CAN-2409 in patients with stage III/IV NSCLC, inadequately responding to ICI treatment. In patients with an inadequate response to ICI treatment (Cohort 1+2, n=46), mOS was 24.5 months. In patients with progressive disease, despite ICI treatment (Cohort 2, n=41), mOS was 21.5 months, which is markedly longer than the 9.8–11.8 months of survival reported in published literature1,2 in the same patient population receiving standard of care of docetaxel chemotherapy. 37% of patients with progressive disease at enrollment were still alive > 24 months after CAN-2409 treatment at the time of the March 3, 2025 data cut, suggesting a long tail of survival. 14/15 patients with overall survival > 24 months and 9/9 patients with overall survival > 30 months had non-squamous NSCLC. In patients with non-squamous NSCLC and progressive disease despite ICI (cohort 2, n=33), observed mOS was 25.4 months after CAN-2409 treatment. A decrease in the size of uninjected tumors was observed in 69% of patients with multiple lesions (n=35), indicating that a local injection is associated with a systemic anti-tumor immune response. CAN-2409 maintained its generally favorable safety and tolerability profile throughout the extended follow-up period. The FDA previously granted Fast Track Designation for CAN-2409 for the treatment of NSCLC. In March 2025, the Company entered a strategic, commercial collaboration with IDEA Pharma, a Division of SAI MedPartners (IDEA). Under this agreement, IDEA will provide strategic commercial input throughout the development and commercialization process for Candel’s lead asset, CAN-2409. Through this collaboration, Candel will gain access to a dedicated team of experts with extensive experience in oncology commercialization and go-to-market strategy optimization. In March 2025, the Company appointed Elizabeth M. Jaffee, M.D., to its Research Advisory Board (RAB). Dr. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, brings her extensive expertise to the RAB, which is important in light of the Company’s focus on borderline resectable pancreatic cancer. Manuscript published in the March 2025 online edition of Neuro-Oncology, reporting results of a phase 1b clinical trial exploring safety and tolerability of the combination of CAN-2409 plus prodrug (valacyclovir) and nivolumab, in addition to standard of care (neurosurgery, radiotherapy, and temozolomide), in patients with newly diagnosed rHGG. Anticipated Milestones Clinical and biomarker activity data from an ongoing phase 1b clinical trial evaluating repeat doses of CAN-3110 in patients with rHGG expected in Q4 2025. Submission of BLA for CAN-2409 in prostate cancer expected in Q4 2026. Financial Results for the First Quarter Ended March 31, 2025 Research and Development Expenses: Research and development expenses were $4.0 million for the first quarter of 2025 compared to $4.1 million for the first quarter of 2024. The decrease was primarily due to a decrease in employee-related expenses, partially offset by an increase in manufacturing costs, in support of the Company’s CAN-2409 programs. Research and development expenses included a non-cash stock compensation expense of ($0.1) million for the first quarter of 2025, as compared to a non-cash stock compensation expense of $0.6 million for the first quarter of 2024. General and Administrative Expenses: General and administrative expenses were $4.1 million for the first quarter of 2025, compared to $3.8 million for the first quarter of 2024. The increase was primarily due to higher professional and consulting fees. General and administrative expenses included non-cash stock compensation expense of $0.4 million for the first quarter of 2025, as compared to a non-cash stock compensation expense of $0.5 million for the first quarter of 2024. Net Income/Loss: Net income for the first quarter of 2025 was $7.4 million compared to a net loss of $8.2 million for the first quarter of 2024 and included net other income of $15.5 million and net other expense of $0.3 million, respectively. The increase in net income was primarily related to the change in the fair value of the Company’s warrant liability. Cash Position: Cash and cash equivalents, as of March 31, 2025, were $92.2 million, as compared to $102.7 million as of December 31, 2024. Based on current plans and assumptions, the Company expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan into the first quarter of 2027. About CAN-2409 CAN-2409 (aglatimagene besadenovec), Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. Because of its versatility, CAN-2409 has the potential to treat a broad range of solid tumors. Encouraging monotherapy activity as well as combination activity with standard of care radiotherapy, surgery, chemotherapy, and ICI have previously been shown in several preclinical and clinical settings. More than 1,000 patients have been dosed with CAN-2409 with a favorable tolerability profile to date, supporting the potential for combination with other therapeutic strategies. Currently, Candel is evaluating CAN-2409 in NSCLC and borderline resectable PDAC and has recently completed a successful phase 3 clinical trial in localized prostate cancer. CAN-2409 plus prodrug (valacyclovir) has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy, and localized primary prostate cancer. Candel’s pivotal phase 3 clinical trial in prostate cancer was conducted under a SPA agreed with the FDA. The FDA has also granted Orphan Drug Designation to CAN-2409 for the treatment of PDAC. About CAN-3110 CAN-3110 is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) next-generation oncolytic viral, immunotherapy candidate designed for dual activity for oncolysis and immune activation in a single therapeutic. CAN-3110 is being evaluated in a phase 1b clinical trial in patients with rHGG. In October 2023, the Company announced that Nature published results from this ongoing clinical trial. CAN-3110 was well tolerated with no dose-limiting toxicity reported. In the clinical trial, the investigators observed improved median overall survival compared to historical controls after a single CAN-3110 injection in this therapy-resistant condition.3 The Company and academic collaborators are currently evaluating the effects of repeat CAN-3110 injections in rHGG, supported by the Break Through Cancer foundation. CAN-3110 has previously received FDA Fast Track Designation and Orphan Drug Designation for the treatment of rHGG. About the enLIGHTEN™ Discovery Platform The enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new multimodal biological immunotherapies for solid tumors. The enLIGHTEN™ Discovery Platform has been designed to deconvolute the characteristics of the tumor microenvironment related to clinical outcomes. These characteristics are rapidly translated into optimized multi-gene payloads of tumor modulators that can be delivered to the tumor microenvironment for specific indications, disease stages, and rationally designed therapeutic combinations. In 2022, the Company announced a discovery partnership with the University of Pennsylvania Center for Cellular Immunotherapies to create new viral immunotherapies that could enhance the efficacy of chimeric antigen receptor T cell (CAR-T) therapy in solid tumors. During the 2023 Society for Immunotherapy of Cancer Annual Meeting and the 2023 International Oncolytic Virotherapy Conference (IOVC) Meeting, Candel presented encouraging data on the first candidate from this platform, Alpha 201-macro-1, which was designed to interfere with the CD47/SIRP1α pathway, in mouse models of breast cancer and lung cancer. During the 2024 American Association for Cancer Research Annual Meeting, Candel presented preclinical data, unveiling the second candidate from the enLIGHTEN™ Discovery Platform, a first-in-class multimodal immunotherapy candidate to induce tertiary lymphoid structures, being developed as a novel therapeutic for solid tumors. Candel also presented data on a multimodal viral therapeutic candidate encoding IL-12 and IL-15 at the 2024 IOVC meeting. About Candel Therapeutics Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and HSV gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and recently completed successful phase 2a clinical trials in NSCLC and PDAC, and a pivotal phase 3 clinical trial in localized prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in rHGG. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: www.candeltx.com Forward-Looking Statements This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, including the timing and availability of additional data and key data readout milestones and presentations; expectations regarding the submission of the BLA for CAN-2409 in intermediate-to-high-risk localized prostate cancer; expectations regarding early biological readouts as predictor of clinical response; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult to treat, solid tumors; and expectations regarding cash runway and expenditures. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor Contact Theodore Jenkins Vice President, Investor Relations, and Business Development Candel Therapeutics, Inc. tjenkins@candeltx.com Media Contact Ben Shannon Vice President ICR Healthcare CandelPR@icrhealthcare.com ______________________________ 1 Paz-Ares LG et al. J Clin Oncol 2024;42:2860-2872 2 Ahn MJ et al. J Clin Onc 2024;43:260-272 3 Ling AL, et al. Nature. 2023;623(7985):157-166. (1) Working capital is calculated as current assets, less current liabilities

临床1期临床结果临床2期快速通道临床3期

2025-04-02

·癌度

《癌度早报2025年4月2日》

癌度临床试验病友交流群（点击）一、新药快讯1、病毒疗法联合免疫治疗，为中晚期非小细胞肺癌带来生存获益CAN-2049是一款腺病毒疗法。近日，根据一项2A期临床试验的最终分析结果，美国病毒疗法CAN-2049与伐昔洛韦或阿昔洛韦及免疫检查点抑制剂联合使用，在三期或四期非小细胞肺癌且对免疫治疗反应不佳的患者带来生存获益。46名可评估患者的平均总生存期为24.5个月。有37%的患者在接受CAN-2409治疗两年后仍然存活。2、创新抗癌疗法LuminICE-203，85%淋巴瘤患者病情显著缓解在第51届欧洲血液与骨髓移植学会年会上，创新疗法LuminICE-203公布了2期临床试验初步数据，AFM13联合AB-101在复发/难治性霍奇金淋巴瘤患者的治疗中展现出显著疗效。在22名接受过大量治疗失败的霍奇金淋巴瘤患者中，有19名患者的肿瘤明显缩小或完全消失，其中12人肿瘤全消失。参与治疗的患者都是经过多种治疗且无效的病人，结果证明该方案不仅起效快，而且疗效可能很持久。3、癌症疫苗VXM01联合免疫疗法，治疗复发性胶质瘤初现疗效一项针对复发性胶质母细胞瘤的人体临床试验中，口服癌症疫苗VXM01联合PD-L1抑制剂阿维鲁单抗，显示出良好的安全性和积极疗效，VXM01是一种口服癌症疫苗，是一种经过改造、对人体无害的沙门氏菌，该细菌作为载体将靶向肿瘤血管的基因片段送入人体。然后激活患者体内的免疫系统，，从而阻断肿瘤供血、抑制肿瘤生长。目前的数据显示，上述治疗对无法手术患者应答率达到了12%，接受过手术患者的中位总生存时间为11.1个月。二、新药快讯1、LS-HB光动力疗法面向多种实体瘤患者开启临床招募LS-HB是一种新的光敏剂，解决了传统卟啉光敏剂稳定型差、容易发生光过敏反应，吸收光谱太短，没办法达到最深治疗的效果。体内试验中，LS-HB介导的光动力疗法让60%的小鼠肿瘤病灶消失，抑制肿瘤的效率达到了92.3%，后续的组织学结果显示，LS-HB介导的光动力疗法引起肿瘤组织坏死和血栓形成，而对照组、单存药物组都没有这些现象。目前光动力疗法已经开始招募实体瘤患者，临床标准治疗失败的患者都可以申请参加。

免疫疗法疫苗临床2期临床3期临床结果

2025-04-01

·ir.candeltx.com

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

NEEDHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the publication of a manuscript reporting the results of a phase 1b clinical trial exploring safety and tolerability of the combination of CAN-2409 plus prodrug (valacyclovir) and nivolumab, in addition to standard of care (neurosurgery, radiotherapy, and temozolomide), in patients with newly diagnosed high-grade glioma. The study, which includes evidence of clinical activity and extensive biomarker analysis, has been published online in Neuro-Oncology, the official journal of the Society for Neuro-Oncology (22 March 2025). High-grade glioma (primarily glioblastoma) remains one of the most aggressive forms of primary brain cancer, affecting more than 13,000 new patients in the United States annually. Despite optimal therapy with surgery, radiation, temozolomide chemotherapy, and, in some cases, tumor-treating fields, the prognosis remains poor with median survival of approximately 20 months from the time of diagnosis for patients without methylguanine methyltransferase (MGMT) promoter methylation and about 2 years for those with MGMT promoter methylation.1 Poor survival is associated with paucity of intratumoral T cell infiltrates and a highly immunosuppressive tumor microenvironment. To date, clinical trials of conventional tumor vaccines and checkpoint inhibitors have failed to demonstrate clinical benefit in this indication. The publication, titled “A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma,” (Wen, P. Y., et al.) demonstrates that the addition of CAN-2409 and nivolumab and standard of care was generally well tolerated and extended survival in a subset of patients with evidence of local and systemic immune activation after experimental treatment. The clinical trial (NCT03576612) enrolled 41 patients, with 35 completing the full treatment regimen, and assayed tumor and blood for genetic and immunological biomarkers before and during treatment. “The results from this mechanistic clinical trial confirm and extend previous observations in clinical trials that have shown clinical and immunological activity of CAN-2409 across different solid tumors,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. “In this trial, treatment with CAN-2409 plus valacyclovir was associated with discrete longitudinal changes in peripheral cytokines, immune cells, and T cell clone diversity, particularly at early timepoints, after patients had been treated with neurosurgery, radiotherapy, and CAN-2409 plus prodrug, but before combination therapy with nivolumab was initiated. The most noteworthy serial systemic immune changes were observed in a long-term survivor subset of patients. While we are not currently developing CAN-2409 for high-grade glioma, in light of portfolio prioritization (We are developing CAN-3110 in recurrent high-grade glioma (rHGG)), the data support the notion that CAN-2409 may be a pan-solid tumor therapy that could invoke individualized anti-cancer immune response in different indications. CAN-2409 is in late-stage development for localized prostate cancer, borderline resectable pancreatic ductal adenocarcinoma, and non-small cell lung cancer (NSCLC).” CAN-2409 is an investigational, off-the-shelf, replication-defective adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to tumor cells. CAN-2409, when administered with valacyclovir, is designed to induce immunogenic cell death of tumor cells with exposure of tumor antigens in the context of an activated tumor microenvironment. Together, this regimen is designed to induce an individualized, systemic, specific CD8+ T cell-mediated response against the tumor, based on in situ vaccination against a variety of the patient’s own tumor antigens. “We are excited by the promising results from this phase 1b clinical trial,” said Francesca Barone, MD, PhD, Chief Scientific Officer of Candel. “Our data demonstrates that CAN-2409 has the potential to broaden the T cell receptor repertoire, and foster a more diverse immune response, which has previously been shown in several publications to be associated with improved clinical outcome in high-grade glioma and other solid tumors. The findings are consistent with previous observations in clinical trials after administration of CAN-2409 in NSCLC and other solid tumors, where CAN-2409 administration led to local and systemic immune cell activation, reinforcing the potential to create a “pipeline in a product” across multiple solid tumors.” Data highlights: Median overall survival for the overall patient population was 15.1 months. A subset of patients with methylated MGMT promoter, who underwent gross total tumor resection (n=6), showed particularly encouraging outcomes, with a median overall survival of 30.6 months. Baseline tumor immune cell composition was associated with clinical outcomes, with patients with higher levels of B cells, dendritic cells, HLA-DR high macrophage clusters, and memory CD4+ T cells exhibiting improved survival. Conversely, we observed a negative correlation between tissue immunosuppressive monocytes and survival. Experimental combination treatment with CAN-2409 plus prodrug and nivolumab induced noteworthy systemic immune activation at weeks 3 and 5 post treatment. This included increased naive and effector T cells, marked reduction in immunosuppressive TIM3+ NK cells, and changes in cytokine profiles observed at weeks 3 and 5 timepoints that were correlated with subsequent survival. Increase in T cell receptor (TCR) density and richness was observed at the week 3 timepoint (after CAN-2409 treatment but before initiation of nivolumab). These changes were associated with improved survival. Long-term survivors (more than 30 months) in the population of patients with MGMT methylated tumors who had undergone gross total resection, showed distinct TCR profiles and immune cell patterns compared to short-term survivors. These included enrichment in TCR richness and diversity, supporting the hypothesis that CAN-2409 can release tumor-associated antigens and broaden the antitumoral T cell response, both locally and systemically. No dose-limiting toxicities attributable to CAN-2409 were observed and a generally favorable safety and tolerability profile of the combination therapy was reported. “The increase in TCR density and richness demonstrated early after experimental treatment with CAN-2409 is an important finding in this phase 1b clinical trial,” said E. Antonio Chiocca, MD, PhD, Chair of the Department of Neurosurgery at Brigham and Women’s Hospital, Professor at Harvard Medical School, Candel Scientific Advisor, and co-author of the publication. “Moreover, we observed an association between TCR diversity and long-term survival in patients with a methylated MGMT promoter, who were able to undergo gross total resection of the tumor, supporting the opportunity for implementation of a novel stratification strategy in future clinical trials.” About CAN-2409 CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic nucleotide analogue that kills nearby cancer cells. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ vaccination against a variety of tumor antigens. Because of its versatility, CAN-2409 has the potential to treat a broad range of solid tumors. Encouraging monotherapy activity, as well as combination activity with standard of care (SoC) radiotherapy, surgery, chemotherapy, and immune checkpoint inhibitors, have previously been shown in several preclinical and clinical settings. More than 1,000 patients have been dosed with CAN-2409 with a generally favorable tolerability profile reported to date, supporting the potential for combination with other therapeutic strategies. Candel's clinical development program for CAN-2409 includes completed phase 2a clinical trials in both NSCLC and pancreatic ductal adenocarcinoma (PDAC), as well as a positive pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in localized, non-metastatic prostate cancer. In December 2024, Candel announced that CAN-2409 achieved its primary endpoint in a phase 3 clinical trial in men with intermediate-to-high-risk, localized prostate cancer, demonstrating statistically significant and clinically meaningful improvement in disease-free survival when added to SoC radiation therapy +/- androgen deprivation therapy. In the Company’s randomized controlled phase 2a clinical trial of CAN-2409 in borderline resectable PDAC, positive survival data showed notable improvement in estimated median overall survival of 31.4 months after experimental treatment with CAN-2409 plus SoC versus 12.5 months in the control group in patients with PDAC who only received SoC. Median survival post-progression was 21.2 months in patients who received CAN-2409 compared to 6.4 months in the control arm. CAN-2409 plus prodrug has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy and localized prostate cancer. The FDA has also granted Orphan Drug Designation to CAN-2409 for the treatment of PDAC. Candel’s pivotal phase 3 clinical trial in newly diagnosed, localized prostate cancer was conducted under a Special Protocol Assessment (SPA) agreed with the FDA. About Candel Therapeutics Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in rHGG. In October 2023, the Company announced that Nature published initial results from this ongoing clinical trial: CAN-3110 was well tolerated and the investigators observed nearly two-fold increase in median overall survival compared to historical controls after a single CAN-3110 injection in this therapy-resistant condition.2 Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: www.candeltx.com Forward-Looking Statements This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; including the timing and availability of additional data and key data readout milestones and presentations; expectations regarding early biological readouts as predictor of clinical response; and expectations regarding the therapeutic benefit of the Company’s programs, including the ability of CAN-2409 to treat a broad range of solid tumors and improve disease-free survival, overall survival, and post-progression survival. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC) including the Company’s most recent Annual Report on Form 10-K filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor Contact: Theodore Jenkins VP, Investor Relations and Business Development Candel Therapeutics, Inc. tjenkins@candeltx.com Media Contact: Ben Shannon ICR Healthcare CandelPR@icrhealthcare.com ____________________________ 1 Stupp R et al. JAMA. 2017; 318(23):2306-2316. 2 Ling AL, et al. Nature. 2023;623(7985):157-166.

临床结果免疫疗法临床1期临床2期快速通道

100 项与 Aglatimagene besadenovec 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15074

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局限性前列腺癌	临床3期	美国	Candel Therapeutics, Inc.	2011-09-01
局限性前列腺癌	临床3期	波多黎各	Candel Therapeutics, Inc.	2011-09-01
转移性非小细胞肺癌	临床2期	美国	Candel Therapeutics, Inc.	2020-10-13
转移性非小细胞肺癌	临床2期	美国	NYU Langone Health	2020-10-13
复发性前列腺癌	临床2期	美国	Candel Therapeutics, Inc.	2016-05-01
复发性前列腺癌	临床2期	墨西哥	Candel Therapeutics, Inc.	2016-05-01
胰腺腺癌	临床2期	美国	Candel Therapeutics, Inc.	2015-10-01
胰腺腺癌	临床2期	墨西哥	Candel Therapeutics, Inc.	2015-10-01
多形性胶质母细胞瘤	临床2期	美国	Candel Therapeutics, Inc.	2007-03-01
脑恶性胶质瘤	临床2期	美国	Candel Therapeutics, Inc.	2007-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04495153 (GlobeNewswire) 人工标引	临床2期	晚期非小细胞肺癌	46	CAN-2409 (cohort 1 and 2)	願範繭蓋膚顧鹽鹽網製(遞壓築範襯選艱憲選衊) = 願窪淵夢膚壓築糧廠窪選齋鏇壓遞廠蓋醖獵願 (膚衊膚齋鏇遞餘餘鏇繭 )	积极	2025-03-26
				CAN-2409 (cohort 2)	願範繭蓋膚顧鹽鹽網製(遞壓築範襯選艱憲選衊) = 鬱願壓膚夢鏇觸膚積積選齋鏇壓遞廠蓋醖獵願 (膚衊膚齋鏇遞餘餘鏇繭 )
NCT02446093 (PaTK02, Company_Website) 人工标引	临床2期	胰腺癌新辅助	13	CAN-2409 + valacyclovir + SoC	窪製夢獵齋夢製憲壓範(壓窪顧廠積壓夢鏇選鏇) = 觸齋壓膚觸鹹壓憲獵齋範衊選遞網鹹願糧鹹顧 (醖鹽遞窪壓鹹積顧顧簾 ) 更多	积极	2025-02-25
				SoC	窪製夢獵齋夢製憲壓範(壓窪顧廠積壓夢鏇選鏇) = 壓淵鹹獵顧選製築製壓範衊選遞網鹹願糧鹹顧 (醖鹽遞窪壓鹹積顧顧簾 ) 更多
NCT01436968 (PipelineReview) 人工标引	临床3期	前列腺癌	745	CAN-2409 plus Standard of care external beam radiation therapy	壓廠壓齋廠築網鬱襯淵(築衊衊衊衊鹹糧選遞衊): HR = 0.7, P-Value = 0.0155 达到更多	积极	2024-12-11
				Standard of care external beam radiation therapy
NCT04495153 (ASCO2024) 人工标引	临床2期	非小细胞肺癌	73	CAN-2409 + valacyclovir	襯選窪夢築膚襯糧艱糧(淵願艱獵獵構築繭願衊) = 獵鏇艱糧願壓膚顧膚襯膚製製窪衊獵餘願衊壓 (鑰衊餘鬱鑰餘廠選構蓋, 14.3 ~ NA) 更多	积极	2024-05-24
				CAN-2409 + valacyclovir (C1, stable disease)	襯選窪夢築膚襯糧艱糧(淵願艱獵獵構築繭願衊) = 淵簾壓膚鏇壓鹹壓鬱壓膚製製窪衊獵餘願衊壓 (鑰衊餘鬱鑰餘廠選構蓋 )
NCT02446093 (PaTK02, Biospace) 人工标引	临床2期	胰腺癌	13	CAN-2409+valacylovir or acyclovir+chemoradiation or SBRT	夢獵衊鹹鏇製蓋衊範壓(艱壓網繭憲憲築鬱壓餘) = none 鹹醖夢醖選願窪夢蓋鹽 (醖築窪繭膚製鬱鹹簾鏇 )	积极	2024-04-04
				chemoradiation or SBRT
NCT00589875 (BrTK02, CTgov)	临床2期	多形性胶质母细胞瘤 \| 脑恶性胶质瘤	52	Radiation therapy+Temozolomide+Valacyclovir+CAN-2409	襯獵簾淵網簾膚糧鏇醖 = 築餘淵積鹽選鏇獵餘壓糧遞艱憲鑰鑰鑰鏇顧觸 (選積窪鏇淵願繭衊顧鹹, 簾鑰蓋襯壓廠網膚蓋範 ~ 齋艱願憲積鑰繭範廠選) 更多	-	2024-04-03
NCT02446093 (PaTK02, SITC2023)	临床2期	局部晚期胰腺腺癌新辅助 soluble granzymes B \| IL-10 \| IFNÎ³	19	CAN-2409+prodrug	範鏇築簾窪觸膚壓繭鹹(顧鬱繭憲窪願夢蓋餘願) = 憲壓艱製鹹觸積糧蓋齋簾艱鏇鏇糧壓廠淵選製 (網遞網廠遞鬱鬱觸願膚 ) 更多	积极	2023-11-02
				CAN-2409+Prodrug (Standard of care (SOC) chemoradiation (CR) and surgery)	範鏇築簾窪觸膚壓繭鹹(顧鬱繭憲窪願夢蓋餘願) = 觸簾膚膚襯夢繭選夢淵簾艱鏇鏇糧壓廠淵選製 (網遞網廠遞鬱鬱觸願膚 ) 更多
NCT04495153 (Corporate Publications) 人工标引	临床2期	非小细胞肺癌二线	40	CAN-2409+valacyclovir+immune checkpoint inhibitor	糧衊製築憲壓鑰繭艱糧(艱齋衊觸鹽夢築憲艱餘) = 鏇鬱鹽遞蓋壓網製膚窪壓繭積夢糧鹽鹹窪淵壓 (獵顧艱蓋餘窪遞廠觸憲 ) 更多	积极	2023-09-26
NCT03576612 (SITC 12022 \| SITC 22022) 人工标引	临床1期	高级别胶质瘤一线	41	valacyclovir+CAN-2409+nivolumab (patients with methylated MGMT promoter undergoing gross total resection (GTR))	糧製獵窪構鹽願膚艱製(壓窪鹽願廠遞壓艱窪艱) = 繭築憲憲鑰選艱顧鏇製構襯淵網觸鑰壓構願艱 (繭簾壓鹹鏇壓醖製齋糧 )	积极	2022-11-01
				valacyclovir+CAN-2409+nivolumab (patients with methylated MGMT promoter undergoing sub-total resection (STR))	糧製獵窪構鹽願膚艱製(壓窪鹽願廠遞壓艱窪艱) = 築夢顧構艱顧鏇鹹鹽糧構襯淵網觸鑰壓構願艱 (繭簾壓鹹鏇壓醖製齋糧 )
NCT04495153 (ASCO2022) 人工标引	临床2期	非小细胞肺癌	28	ICI+Aglatimagene besadenovec (stable disease)	遞憲築鬱製鏇襯膚製壓(鏇窪窪膚簾製繭鹽築繭) = Of the 14 RECIST evaluable patients who received 2 doses of CAN-2409, clinical response was seen in 4 patients 衊觸壓獵蓋鹽淵鏇遞壓 (繭構鏇積窪顧獵簾鏇積 ) 更多	积极	2022-06-02
				ICI+Aglatimagene besadenovec (progressive disease after ≥18 weeks)